Castleark Management LLC bought a new stake in shares of Novanta Inc. (NASDAQ:NOVT – Free Report) during the 1st quarter, according to its most recent filing with the SEC. The firm bought 34,990 shares of the technology company’s stock, valued at approximately $4,133,000. Castleark Management LLC owned 0.10% of Novanta as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NOVT. Danske Bank A S acquired a new stake in Novanta in the third quarter valued at $40,000. Allworth Financial LP boosted its holdings in Novanta by 978.4% in the fourth quarter. Allworth Financial LP now owns 399 shares of the technology company’s stock worth $47,000 after purchasing an additional 362 shares during the period. EverSource Wealth Advisors LLC increased its stake in Novanta by 120.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 427 shares of the technology company’s stock valued at $51,000 after purchasing an additional 233 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in Novanta during the fourth quarter valued at $53,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Novanta by 1,291.4% during the fourth quarter. Farther Finance Advisors LLC now owns 487 shares of the technology company’s stock worth $58,000 after purchasing an additional 452 shares during the period. Hedge funds and other institutional investors own 98.35% of the company’s stock.
Novanta Price Performance
NASDAQ:NOVT opened at $140.80 on Tuesday. The firm has a market cap of $5.32 billion, a P/E ratio of 102.03 and a beta of 1.67. Novanta Inc. has a 52-week low of $98.27 and a 52-week high of $171.85. The company has a quick ratio of 2.69, a current ratio of 3.56 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $155.42 and its 200 day moving average price is $140.42.
Analysts Set New Price Targets
NOVT has been the topic of several research reports. Wall Street Zen upgraded shares of Novanta from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Weiss Ratings restated a “hold (c-)” rating on shares of Novanta in a research note on Wednesday, July 15th. Finally, Robert W. Baird set a $180.00 target price on Novanta in a report on Tuesday, June 9th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $180.00.
Get Our Latest Stock Analysis on Novanta
Insider Buying and Selling
In other Novanta news, CEO Matthijs Glastra sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $150.43, for a total value of $1,128,225.00. Following the completion of the sale, the chief executive officer directly owned 42,761 shares of the company’s stock, valued at $6,432,537.23. The trade was a 14.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.20% of the stock is owned by company insiders.
About Novanta
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
Further Reading
- Five stocks we like better than Novanta
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT – Free Report).
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
